Biological evaluation of 153Sm and 166Ho complexes with tetraazamacrocycles containing methylcarboxylate and/or methylphosphonate pendant arms

Radiochimica Acta

Volumn 95, Issue 6, 2007, Pages 335-341

  Marques, F ^a   Gano, L ^a   Campello, M P ^a   Lacerda, S ^a   Santos, I ^a  

^a INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

Author keywords

Biodistribution; Carboxylates; Phosphonates; Radiolanthanides; Tetraazamacrocycles; Therapy

Indexed keywords

EID: 34250729721     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2007.95.6.335     Document Type: Article

References (53)

1. Volkert, W. A., Hoffman, T. J.: Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269 (1999).
2. Chatal, J. F., Hoefnagel, C. A.: Radionuclide therapy. Lancet 354, 931 (1999).
3. Ercan, M. T., Caglar, M.: Therapeutic radiopharmaceuticals. Curr. Pharm. Des. 6, 1085 (2000).
4. Carlsson, J., Aronsson, E. F., B. Hietala, S. O., Stigbrand, T., Tennvall, J.: Tumour therapy with radionuclides: assessment of progress and problems. Radiotherapy Oncology 66, 107 (2003).
5. Volkert, W. A., Goeckeler, W. F., Ehrhardt, G. J., Ketring, A. R.: Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med. 32, 174 (1991).
6. Neves, M., Kling, A., Lambrecht, R. M.: Radionuclide production for therapeutic radiopharmaceuticals. Appl. Radiat. Isotopes 57, 657 (2002).
7. Rösch, F., Forsell-Aronsson, E.: Radiolanthanides in Nuclear Medicine. In: Metal Ions in Biological Systems, vol. 42: Metal Complexes in Tumour Diagnosis and as Anticancer Agents. (Siegel, A., Siegel, H., eds.) Marcel Decker, Inc., New York (2004), p. 77.
8. Froidevaux, S., Eberle, A. N.: Somatostatin analogues and radiopeptides in cancer therapy. Biopolymers 66, 161 (2002).
9. Weiner, R. E., Thakur, M. L.: Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isotopes 57, 749 (2002).
10. Smith, C. J., Volkert, W. A., Hoffman, T. J.: Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise uptake. Nucl. Med. Biol. 30, 861 (2003).
11. 3- octreotate in tumor-bearing rats. Nucl. Med. Biol. 28, 327 (2001).
12. 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging 30, 917 (2003).
13. 149Pm. Nucl. Med. Biol. 30, 241 (2003).
14. 2: An in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl. Med. Biol. 30, 101 (2003).
15. 177Lu-DOTA- lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl. Med. Biol. 31, 753 (2004).
16. Zhang, H., Chen, J., Waldherr, C., Hinni, K., Waser, B., Reubi, J. C., Maecke, H. R.: Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 64, 6707 (2004).
17. Oriushi, N., Higuchi, T., Hanaoka, H., Iida, Y., Endo, K.: Current status of cancer therapy with radiolabeled monoclonal antibody. Ann. Nucl. Med. 19, 355 (2005).
18. Polakis, P.: Arming antibodies for cancer therapy. Curr. Opin. Pharmacol. 5, 382 (2005).
19. Qu, Z., Griffiths, G. L., Wegener, W. A., Chang, C. H., Govindan, S. V., Horak, I. D., Hansen, H. J., Goldenberg, D. M.: Development of humanized antibodies as cancer therapeutics. Methods 36, 84 (2005).
20. 153Sm for potential use in radioimmunotherapy. Appl. Radiat. Isotopes 57, 665 (2002).
21. Dadachova, E., Mirzadeh, S., Smith, S. V., Knapp Jr., F. F., Hetherington, E. L.: Radiolabeling antibodies with holmium-166. Appl. Radiat. Isotopes 48, 477 (1997).
22. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., LoBuglio, A. F.: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37, 1491 (1996).
23. 177Lu for radioimmunotherapy applications. Nucl. Med. Biol. 29, 431 (2002).
24. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl. Med. Biol. 32, 269 (2005).
25. Sharkey, R. M., Karacay, H., Cardillo, T. M., Chang, C. H., McBride, W. J., Rossi, E. A., Horak, I. D., Goldenberg, D. M.: Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res 11, 7109s (2005).
26. 177Lu-DOTA-Biotin pretargeted by CC49 scFv-streptavidin fusion protein in Xenograft-bearing nude mice. Nucl. Med. Biol. 31, 213 (2004).
27. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur. J. Nucl. Med. Mol. Imaging 264, 32 (2005).
28. Langer, M., Beck-Sickinger, A. G.: Peptides as carrier for tumour diagnosis and treatment. Curr. Med. Chem. Anti-Canc. Agents 1, 71 (2001).
29. Liu, S., Edwards, D. S.: Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7 (2001).
30. Chappell, L. L., Ma, D., Milenic, D. E., Garmestani, K., Venditto, V., Beitzel, M. P., Brechbiel, M. W.: Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid for radiolabeling proteins. Nucl. Med. Biol. 30, 581 (2003).
31. Goeckeler, W. F., Edwards, B., Volkert, W. A., Holmes, R. A., Simon, J., Wilson, D.: Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 28, 495 (1987).
32. Logan, K. W., Volkert, W. A., Holmes, R. A.: Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J. Nucl. Med. 28, 505 (1987).
33. Liepe, K., Runge, R., Kotzerke, J.: The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J. Cancer Res. Clin. Oncol. 131, 60 (2005).
34. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur. J. Nucl. Med. Mol. Imaging 31, S171 (2004).
35. 166Ho-EDTMP. Blood 80, 1608 (1992).
36. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl. Med. Commun. 19, 587 (1998).
37. Serafini, A. N.: Therapy of metastatic bone pain. J. Nucl. Med. 42, 895 (2001).
38. Finlay, I. G., Mason, M. D., Shelley, M.: Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 6, 392 (2005).
39. Alves, F. C., Donato, P., Sherry, A. D., Zaheer, A., Zhang, S., Lubag, A. J. M., Merritt, M. E., Lenkinski, R. E., Frangioni, J. V., Neves, M., Prata, M. I. M., Santos, A. C., de Lima, J. J. P., Geraldes, C. F. G. C.: Silencing of phosphonate-gadolinium magnetic resonance imaging contrast by hydroxyapatite binding. Invest. Radiol. 38, 750 (2003).
40. 153Sm-DOTMP as a potential agent for bone pain palliation. Nucl. Med. Commun. 25, 1169 (2004).
41. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isotopes 57, 177 (2002).
42. Bayouth, J. E., Macey, D. J., Kasi, L. P., Garlich, J. R., Mcmillan, K., Dimopoulos, M. A., Champlin, R. E.: Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med. 36, 730 (1995).
43. 166Ho-DOTMP. Cancer Biotherapy Radiopharm. 18, 225 (2003).
44. Pandit-Taskar, N., Batraki, M., Divgi, C. R.: Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J. Nucl. Med. 45, 1358 (2004).
45. Bagi, C. M.: Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Delivery Rev. 57, 995 (2005).
46. Kubiček, V., Rudovský, J., Kotek, J., Herrman, P., Elst, L. V., Muller, R. N., Kolar, Z. I., Wolterbeek, H. T., Peters, J. A., Lukeš, I.: A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J. Am. Chem. Soc. 127, 16477 (2005).
47. 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms. J. Biol. Inorg. Chem. 9, 859 (2004).
48. 166Ho complexes as potential agents for therapy or bone pain palliation. J. Inorg. Biochem. 100, 270 (2006).
49. 166Ho complexes anchored by a novel bis(methylphosphonate) tetraazamacrocycle. Radiochim. Acta 95, 329 (2007).
50. Chang, C. A., Liu, Y. L., Chen, C. Y., Chou, X. M.: Ligand pre-organization in metal ion complexation.: molecular mechanics/dynamics, kinetics, and laser-excited luminescence studies of trivalent lanthanide complex formation with macrocyclic ligands TETA and DOTA. Inorg. Chem. 40, 3448 (2001).
51. Delgado, R., Costa, J., Guerra, K. P., Lima, L. M. P.: Lanthanide complexes of macrocyclic derivatives useful for medical applications. Pure Appl. Chem. 77, 569 (2005).
52. Neumaier, B., Rösch, F.: Ternary complex formation of lanthanides and radiolanthanides with phosphate and serum proteins. Radiochim. Acta 84, 201 (1999).
53. Kim, W. D., Kiefer, G. E., Maton, F., McMillan, K., Muller, R. N., Sherry, A. D.: Relaxometry, luminescence measurements, electrophoresis, and animal biodistribution of lanthanide(III) complexes of some polyaza macrocyclic acetates containing pyridine. Inorg. Chem. 34, 2233 (1995).